Kaléo Enters Into Licensing Agreement With Valeo Pharma For The Canadian Rights to ALLERJECT®(epinephrine injection, USP)

Richmond, Va – Kaléo, a privately held U.S. pharmaceutical company, today announced that

it has entered into a ten-year License, Supply, and Commercialization agreement with Valeo Pharma, a

Canadian pharmaceutical company, for the Canadian rights to ALLERJECT® (epinephrine injection, USP) for the

treatment of severe allergic reactions.

“Patients with life threatening allergies across Canada deserve access to this innovative and potentially

lifesaving product,” said Kaléo President and CEO Ronald Gunn. “Valeo Pharma’s sales force, relationships with

the healthcare community, and commitment to patients make them the ideal partner for ALLERJECT.”

For more information please click here.

Transforming the finance function in life sciences: Empower scalable growth

Life sciences companies operate in one of the most complex business environments. Long R&D timelines, limited early-stage revenue, and dependence on external funding create a financial landscape where every decision carries strategic weight. In this context, finance is not a back-office function. It is an operational engine that drives whether a company survives, scales, or …

08/11/2026

Pascal Medical Corporation Secures $3.8M to Advance ClickGel Into Pivotal Large Animal Testing

Pascal Medical Corporation has raised $3.8 million to push its ClickGel surgical sealant through pivotal large animal testing on the way to human trials. The total combines a $3 million private financing round closed in July with an $800,000 grant from Virginia Catalyst, announced by Governor Abigail Spanberger on July 30, 2026. Pascal will use …

08/10/2026

Expanding visibility with wearable blood pressure monitoring: CareTaker

In higher-risk patient populations, across all points of care, a patient’s condition can deteriorate quickly between routine vital sign checks, creating critical gaps in visibility and leaving clinical deterioration undetected between rounds. Continuous clinical-grade non-invasive blood pressure (CNIBP) monitoring, combined with hemodynamic trending, helps close these gaps by providing a more complete view of patient …

News